Role of TRPV channels in the pathogenesis of Systemic Sclerosis vasculopathy

TRPV 通道在系统性硬化症血管病发病机制中的作用

基本信息

  • 批准号:
    9034722
  • 负责人:
  • 金额:
    $ 8.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-04-01 至 2016-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Transient receptor potential (TRP) channels are a superfamily of polymodal receptor cation channels that mediate environmental and sensory signal transduction. TRP cation channel, subfamily V (TRPV) members are sensitive to various environmental stimuli such as: temperature changes, osmosensitivity and stress, and their ubiquitous expression suggests a role in both sensory and nonsensory transduction. Recently, we made the highly provocative observation that TRPV2 was profoundly underexpressed (greater than 20-fold) in Systemic Sclerosis (SSc) dermal fibroblasts compared to those from normal individuals, suggesting that TRPV channels may play a role in the pathogenesis of SSc. Other published studies have shown that TRPV1 and TRPV4 participate in the development of fibrotic lesions in animal models of fibrosis. Based on these studies we propose the hypothesis that: TGF-ß and TRPV channels establish an autocrine loop in fibroblasts and endothelial cells (EC) where TGF-ß expression decreases the expression of TRPV1 and TRPV2 and induces the expression of TRPV4. The reduction of TRPV1 and TRPV2 and the increase in TRPV4 in turn induce and maintain elevated TGF-ß levels creating a repetitive cycle which triggers myofibroblast differentiation in quiescent fibroblasts and induces endothelial to mesenchymal transition (EndoMT) in EC resulting in progressive tissue fibrosis and fibroproliferative vasculopathy. To test this hypothesis we will pursue the following Specific Aims: SPECIFIC AIM 1: Examine the effects of TRPV1, TRPV2 and TRPV4 agonists and antagonists in the presence and absence of TGF-ß, on the expression of profibrotic genes and of genes associated with myofibroblast activation in human dermal fibroblasts and with EndoMT in human dermal and pulmonary microvascular EC. SPECIFIC AIM 2: Evaluate the in vivo effects of Trpv1, Trpv2 and Trpv4 knockout employing the TGF-ss overexpression murine model of tissue fibrosis. Since there is currently no effective disease-modifying therapy to improve the devastating health consequences and high mortality associated with SSc, an urgent unmet need exists to identify potential targets to develop such therapies. The strengths of this proposal are: 1. It is supported by strong Preliminary Data demonstrating that alterations of the activity of TRPV1 and TRPV2 participate in the phenotypic differentiation of fibroblasts into activated myofibroblasts and in te induction of EndoMT in murine EC; and 2. They will provide valuable information regarding the initial molecular events that couple sensory signal transduction, inflammation and fibrosis in SSc. Thus, we believe these studies may provide important clues regarding SSc pathogenesis, and may identify potential novel therapeutic targets for this currently incurable disease.
描述(由申请人提供):瞬时受体电位(TRP)通道是介导环境和感觉信号转导的多模态受体阳离子通道超家族。TRP阳离子通道V亚家族(TRPV)成员对各种环境刺激如温度变化、温度敏感性和应激敏感,并且它们的普遍表达暗示了在感觉和非感觉转导中的作用。最近,我们进行了高度挑衅性的观察,即TRPV 2在系统性硬化症(SSc)皮肤成纤维细胞中的表达低于正常人,这表明TRPV通道可能在SSc的发病机制中发挥作用。其他已发表的研究表明,TRPV 1和TRPV 4参与纤维化动物模型中纤维化病变的发展。基于这些研究,我们提出以下假设:TGF-β和TRPV通道在成纤维细胞和内皮细胞(EC)中建立自分泌环,其中TGF-β表达降低TRPV 1和TRPV 2的表达并诱导TRPV 4的表达。TRPV 1和TRPV 2的减少以及TRPV 4的增加进而诱导并维持升高的TGF-β 1水平,从而产生重复循环,其触发静止成纤维细胞中的肌成纤维细胞分化并诱导EC中的内皮向间充质转化(EndoMT),导致进行性组织纤维化和纤维增生性血管病。具体目的1:检测在存在和不存在TGF-β的情况下TRPV 1、TRPV 2和TRPV 4激动剂和拮抗剂对促纤维化基因和与人真皮成纤维细胞中的肌成纤维细胞活化相关的基因以及与人真皮和肺微血管EC中的EndoMT相关的基因的表达的影响。具体目的2:使用组织纤维化的TGF-β过表达鼠模型评价Trpv 1、Trpv 2和Trpv 4敲除的体内作用。由于目前没有有效的疾病修饰疗法来改善与SSc相关的破坏性健康后果和高死亡率,因此迫切需要确定开发此类疗法的潜在靶标。该建议的优点是:1。之表示支持 通过强有力的初步数据证明TRPV 1和TRPV 2活性的改变参与成纤维细胞向活化的肌成纤维细胞的表型分化和小鼠EC中EndoMT的诱导;和2.他们将提供有价值的信息,关于耦合感觉信号转导,炎症和纤维化的SSc的初始分子事件。因此,我们相信这些研究可能提供有关SSc发病机制的重要线索,并可能为这种目前无法治愈的疾病确定潜在的新治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

SERGIO A JIMENEZ其他文献

SERGIO A JIMENEZ的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('SERGIO A JIMENEZ', 18)}}的其他基金

Serum Exosome MicroRNA in Systemic Sclerosis
系统性硬化症中的血清外泌体 MicroRNA
  • 批准号:
    9299047
  • 财政年份:
    2017
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of TRPV channels in the pathogenesis of Systemic Sclerosis vasculopathy
TRPV 通道在系统性硬化症血管病发病机制中的作用
  • 批准号:
    8702580
  • 财政年份:
    2014
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of TRPV channels in the pathogenesis of Systemic Sclerosis vasculopathy
TRPV 通道在系统性硬化症血管病发病机制中的作用
  • 批准号:
    8826028
  • 财政年份:
    2014
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of toll like receptors (TLRs)in Gd contrast agent induced skin fibrosis
Toll样受体(TLRs)在Gd造影剂诱导的皮肤纤维化中的作用
  • 批准号:
    8549103
  • 财政年份:
    2012
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of toll like receptors (TLRs)in Gd contrast agent induced skin fibrosis
Toll样受体(TLRs)在Gd造影剂诱导的皮肤纤维化中的作用
  • 批准号:
    8301981
  • 财政年份:
    2012
  • 资助金额:
    $ 8.12万
  • 项目类别:
Identification of Novel Markers for Systemic Sclerosis Employing Proteomics
利用蛋白质组学鉴定系统性硬化症的新标记物
  • 批准号:
    8125088
  • 财政年份:
    2010
  • 资助金额:
    $ 8.12万
  • 项目类别:
Identification of Novel Markers for Systemic Sclerosis Employing Proteomics
利用蛋白质组学鉴定系统性硬化症的新标记物
  • 批准号:
    7979478
  • 财政年份:
    2010
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of Caveolin in Scleroderma Tissue Fibrosis and Vasculopathy
Caveolin 在硬皮病组织纤维化和血管病变中的作用
  • 批准号:
    8078005
  • 财政年份:
    2008
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of Caveolin in Scleroderma Tissue Fibrosis and Vasculopathy
Caveolin 在硬皮病组织纤维化和血管病变中的作用
  • 批准号:
    8270386
  • 财政年份:
    2008
  • 资助金额:
    $ 8.12万
  • 项目类别:
Role of Caveolin in Scleroderma Tissue Fibrosis and Vasculopathy
Caveolin 在硬皮病组织纤维化和血管病变中的作用
  • 批准号:
    7533226
  • 财政年份:
    2008
  • 资助金额:
    $ 8.12万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 8.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 8.12万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 8.12万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了